Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001833214-25-000003
Filing Date
2025-08-19
Accepted
2025-08-19 16:30:03
Documents
7
Period of Report
2025-08-19

Document Format Files

Seq Description Document Type Size
1 PRE 14A sabs_pre14a_series_b_off.htm PRE 14A 502309
2 GRAPHIC img215988174_0.jpg GRAPHIC 127616
3 GRAPHIC img215988174_1.jpg GRAPHIC 5049
4 GRAPHIC img215988174_2.jpg GRAPHIC 6824
5 GRAPHIC img215988174_3.jpg GRAPHIC 5183
6 GRAPHIC img215988174_4.jpg GRAPHIC 490860
7 GRAPHIC img215988174_5.jpg GRAPHIC 166396
  Complete submission text file 0001833214-25-000003.txt   1608004
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-39871 | Film No.: 251232197
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)